At a glance
ClinicalIndex Comparison RecordN/ACompleted· 70 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
In Brief
An observational study for Non-squamous NSCLC. Completed, enrolled 70 participants across 1 site.
Detailed Summary
This study aimed to explore the efficacy of Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Non-squamous NSCLC.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon-squamous NSCLC
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartSep 2019
Primary CompletionMay 2021
Study CompletionSep 2021
First PostedMar 2022
TodayJul 2026
First PostedMar 2, 2022
Enrollment StartSep 1, 2019
Primary CompletionMay 1, 2021
Study CompletionSep 15, 2021
TodayJul 1, 2026
Enrollment to primary: 1.7 yearsPosted 4.3 years ago